Cited by 351

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Stability of Circulating Blood-Based MicroRNAs – Pre-Analytic Methodological Considerations

Glinge, Charlotte, Clauss, Sebastian, Boddum, Kim, Jabbari, Reza, Jabbari, Javad, Risgaard, Bjarke, Tomsits, Philipp, Hildebrand, Bianca, Kääb, Stefan, Wakili, Reza, Jespersen, Thomas, Tfelt-Hansen, Jacob·2017·PLOS ONE

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0167969

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Different blood tubes for miRNA analysis. miRNA was isolated and levels of miR-1, miR-21 and miR-29b from either; EDTA-plasma, citrate-plasma, lithium-heparin-plasma, or serum fraction, were detected by RT-qPCR. Values were normalized to a spike-in control, cel-miR-39. Normalized average ΔCT values for each are shown, demonstrating amplification from all sources, except lithium-heparin-plasma. In the remaining samples, the levels of miR-21 and miR-29b did not vary significantly between the blood tubes. Li = lithium, ND = not detectable. A) Copenhagen Cohort. B) Munich Cohort.
Fig 1 Different blood tubes for miRNA analysis. miRNA was isolated and levels of miR-1, miR-21 and miR-29b from either; EDTA-plasma, citrate-plasma, lithium-heparin-plasma, or serum fraction, were detected by RT-qPCR. Values were normalized to a spike-in control, cel-miR-39. Normalized average ΔCT values for each are shown, demonstrating amplification from all sources, except lithium-heparin-plasma. In the remaining samples, the levels of miR-21 and miR-29b did not vary significantly between the blood tubes. Li = lithium, ND = not detectable. A) Copenhagen Cohort. B) Munich Cohort.CC BY · PubMed Central
Fig 2 Stability of miRNA in whole blood incubated at room temperature. Whole blood was collected into EDTA containing tubes and incubated for 0, 4, 8, 12, 24 and 72 h at room temperature before processed into plasma. qRT-PCR was performed. Statistically significant differences in miRNA expression are marked with asterisks (**). **p<0.01. A) miR-21. B) miR-29b.
Fig 2 Stability of miRNA in whole blood incubated at room temperature. Whole blood was collected into EDTA containing tubes and incubated for 0, 4, 8, 12, 24 and 72 h at room temperature before processed into plasma. qRT-PCR was performed. Statistically significant differences in miRNA expression are marked with asterisks (**). **p<0.01. A) miR-21. B) miR-29b.CC BY · PubMed Central
Fig 3 Impact of delayed processing on separated blood fractions. Whole blood was collected into EDTA or serum separator containing tubes and incubated at room temperature for 0h, 24h, and 4 days before processed into plasma (A) and serum (B) or processed into plasma (C) and serum (D) immediately and then incubated at room temperature for 0h, 24h, and 4d. Data presented as normalized average ΔCTvalues±SEM. *p<0.05, **p<0.01, ***p<0.001.
Fig 3 Impact of delayed processing on separated blood fractions. Whole blood was collected into EDTA or serum separator containing tubes and incubated at room temperature for 0h, 24h, and 4 days before processed into plasma (A) and serum (B) or processed into plasma (C) and serum (D) immediately and then incubated at room temperature for 0h, 24h, and 4d. Data presented as normalized average ΔCTvalues±SEM. *p<0.05, **p<0.01, ***p<0.001.CC BY · PubMed Central
Fig 4 Impact of physical disturbance. Whole blood was collected into EDTA or serum separator containing tubes and incubated on a shaker at 30 rpm at room temperature for 0h, 1h, and 8h before processed into plasma (A) and serum (B) or processed into plasma (C) and serum (D) immediately and then incubated on a shaker at 30 rpm at room temperature for 0 h, 1 h, and 8 h. Data presented as normalized average ΔCTvalues±SEM. *p<0.05, **p<0.01, One-way ANOVA with Dunnet post test.
Fig 4 Impact of physical disturbance. Whole blood was collected into EDTA or serum separator containing tubes and incubated on a shaker at 30 rpm at room temperature for 0h, 1h, and 8h before processed into plasma (A) and serum (B) or processed into plasma (C) and serum (D) immediately and then incubated on a shaker at 30 rpm at room temperature for 0 h, 1 h, and 8 h. Data presented as normalized average ΔCTvalues±SEM. *p<0.05, **p<0.01, One-way ANOVA with Dunnet post test.CC BY · PubMed Central
Fig 5 Incubation of plasma at -80°C for up to 9 months. There was no significant change in miRNA concentration up to 9 months after freezing for either miR-21 (A) or miR-29b (B) in plasma (p = 0.11 and p = 0.96). However, the concentration of both miRNAs in whole blood increased during storage at -80°C. *p<0.05, **p<0.01.
Fig 5 Incubation of plasma at -80°C for up to 9 months. There was no significant change in miRNA concentration up to 9 months after freezing for either miR-21 (A) or miR-29b (B) in plasma (p = 0.11 and p = 0.96). However, the concentration of both miRNAs in whole blood increased during storage at -80°C. *p<0.05, **p<0.01.CC BY · PubMed Central
Fig 6 MiRNA stability after repetitive freeze-thaw cycles within the separated fractions. Whole blood was collected into EDTA or serum separator containing tubes, immediately processed into plasma (A) and serum (B) and frozen at -80°C. Samples were thawed one or four times before RNA was isolated and RT-qPCR was performed. *p<0.05, **p<0.01, unpaired student t-test.
Fig 6 MiRNA stability after repetitive freeze-thaw cycles within the separated fractions. Whole blood was collected into EDTA or serum separator containing tubes, immediately processed into plasma (A) and serum (B) and frozen at -80°C. Samples were thawed one or four times before RNA was isolated and RT-qPCR was performed. *p<0.05, **p<0.01, unpaired student t-test.CC BY · PubMed Central
Fig 7 MiRNA levels in the 3 blood fractions; plasma, buffy coat and red blood cells (RBC). The two miRNAs, miR-21 and miR-29b, were differently distributed in the fractions; there are significant higher levels of miR-21 in the buffy coat and RBC compared to plasma, and miR-29b plasma levels are significantly lower than in the buffy coat. Statistically significant differences in miRNA expression are marked with asterisks (*).**p<0.01, ***p<0.001.
Fig 7 MiRNA levels in the 3 blood fractions; plasma, buffy coat and red blood cells (RBC). The two miRNAs, miR-21 and miR-29b, were differently distributed in the fractions; there are significant higher levels of miR-21 in the buffy coat and RBC compared to plasma, and miR-29b plasma levels are significantly lower than in the buffy coat. Statistically significant differences in miRNA expression are marked with asterisks (*).**p<0.01, ***p<0.001.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 26

  1. J Lu, 2005, MicroRNA expression profiles classify human cancers, Nature, 435, 834, 10.1038/nature03702 · DOI
  2. S Gilad, 2008, Serum microRNAs are promising novel biomarkers, PloS One, 3, e3148, 10.1371/journal.pone.0003148 · DOI
  3. G-K Wang, 2010, Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans, Eur Heart J, 31, 659, 10.1093/eurheartj/ehq013 · DOI
  4. AJ Tijsen, 2010, MiR423-5p as a circulating biomarker for heart failure, Circ Res, 106, 1035, 10.1161/CIRCRESAHA.110.218297 · DOI
  5. MP Perron, 2007, Regulatory RNAs: future perspectives in diagnosis, prognosis, and individualized therapy, Methods Mol Biol Clifton NJ, 361, 311
  6. Y D’Alessandra, 2010, Circulating microRNAs are new and sensitive biomarkers of myocardial infarction, Eur Heart J, 31, 2765, 10.1093/eurheartj/ehq167 · DOI
  7. N Bushati, 2007, microRNA functions, Annu Rev Cell Dev Biol, 23, 175, 10.1146/annurev.cellbio.23.090506.123406 · DOI · Paper page
  8. RW Carthew, 2009, Origins and Mechanisms of miRNAs and siRNAs, Cell, 136, 642, 10.1016/j.cell.2009.01.035 · DOI
  9. AS Flynt, 2008, Biological principles of microRNA-mediated regulation: shared themes amid diversity, Nat Rev Genet, 9, 831, 10.1038/nrg2455 · DOI
  10. DP Bartel, 2004, MicroRNAs: genomics, biogenesis, mechanism, and function, Cell, 116, 281, 10.1016/S0092-8674(04)00045-5 · DOI
  11. PS Mitchell, 2008, Circulating microRNAs as stable blood-based markers for cancer detection, Proc Natl Acad Sci U S A, 105, 10513, 10.1073/pnas.0804549105 · DOI · Paper page
  12. SSC Chim, 2008, Detection and characterization of placental microRNAs in maternal plasma, Clin Chem, 54, 482, 10.1373/clinchem.2007.097972 · DOI
  13. CH Lawrie, 2008, Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma, Br J Haematol, 141, 672, 10.1111/j.1365-2141.2008.07077.x · DOI
  14. JS McDonald, 2011, Analysis of circulating microRNA: preanalytical and analytical challenges, Clin Chem, 57, 833, 10.1373/clinchem.2010.157198 · DOI
  15. O Gidlöf, 2011, Cardiospecific microRNA plasma levels correlate with troponin and cardiac function in patients with ST elevation myocardial infarction, are selectively dependent on renal elimination, and can be detected in urine samples, Cardiology, 118, 217, 10.1159/000328869 · DOI
  16. M Hanke, 2010, A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer, Urol Oncol, 28, 655, 10.1016/j.urolonc.2009.01.027 · DOI
  17. NJ Park, 2009, Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection, Clin Cancer Res Off J Am Assoc Cancer Res, 15, 5473, 10.1158/1078-0432.CCR-09-0736 · DOI
  18. JA Weber, 2010, The microRNA spectrum in 12 body fluids, Clin Chem, 56, 1733, 10.1373/clinchem.2010.147405 · DOI · Paper page
  19. J Rice, 2015, Assay reproducibility in clinical studies of plasma miRNA, PloS One, 10, e0121948, 10.1371/journal.pone.0121948 · DOI
  20. K Wang, 2012, Comparing the MicroRNA spectrum between serum and plasma, PloS One, 7, e41561, 10.1371/journal.pone.0041561 · DOI
  21. LT Weckbach, 2016, MicroRNAs as a diagnostic tool for heart failure and atrial fibrillation, Curr Opin Pharmacol, 27, 24, 10.1016/j.coph.2016.01.001 · DOI
  22. JR Chevillet, 2014, Quantitative and stoichiometric analysis of the microRNA content of exosomes, Proc Natl Acad Sci U S A, 111, 14888, 10.1073/pnas.1408301111 · DOI
  23. P Tiberio, 2015, Challenges in using circulating miRNAs as cancer biomarkers, BioMed Res Int, 2015, 731479, 10.1155/2015/731479 · DOI
  24. MB Kirschner, 2011, Haemolysis during sample preparation alters microRNA content of plasma, PloS One, 6, e24145, 10.1371/journal.pone.0024145 · DOI · Paper page
  25. H Zhao, 2014, Effects of preanalytic variables on circulating microRNAs in whole blood, Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol, 23, 2643, 10.1158/1055-9965.EPI-14-0550 · DOI
  26. NH Farina, 2014, Standardizing Analysis of Circulating MicroRNA: Clinical and Biological Relevance, J Cell Biochem, 115, 805, 10.1002/jcb.24745 · DOI

Cited by

Sorted by citations

See all 351

Metadata

Authors
Glinge, C., Clauss, S., Boddum, K., Jabbari, R., Jabbari, J., Risgaard, B., Tomsits, P., Hildebrand, B., Kääb, S., Wakili, R., Jespersen, T., & Tfelt-Hansen, J.
Venue
PLOS ONE
Published
2017-02-02
Volume
12
Issue
2
Pages
e0167969
ISSN
1932-6203
Cited by
351
References
5
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review